And yet MORE good news on GLP-1s

We almost need a separate GLP-1 newsletter. Added to other great news this week (see below), the FDA just cleared Ozempic for treatment of chronic kidney disease in diabetics.

Four days ago, Novo Nordisk (the manufacturer of Ozempic) got good news on their next generation weight loss drug, amycretin. Amycretin mimics the gut hormone GLP-1, but it also mimics the effect of a hunger-suppressing pancreatic hormone called amylin.

And just a week ago, a huge Veterans Administration study was published with unexpected findings from …